Stealth liposomal doxorubicin vs carboplatin/paclitaxel in patients with ovarian cancer recurrence between six and twelve months after previous platinum based chemotherapy: phase III multicenter randomized study

(i) To test the hypothesis that the artificial prolongation of the platinum-free interval with a non-platinum will improve the effectiveness of overall therapy in patients with ovarian cancer progression occurring 6-12 months after first-line treatment with a platinum-derivative. (ii) To evaluate if the sequence of stealth liposomal doxorubicin followed at a later progression by carboplatin/paclitaxel is superior to the inverse sequence of treatment (carboplatin/paclitaxel followed at a later progression bu stealth liposomal doxorubicin). The primary endpoint is overall survival.